Malignant Neoplasm of Stomach Recruiting Phase 3 Trials for Capecitabine (DB01101)

Also known as: Gastric Cancers / Stomach Cancer / Gastric cancer / Gastric Malignancies / Gastric cancer NOS / Cancer of Stomach / Malignant neoplasm of stomach, unspecified / Gastric malignancy

IndicationStatusPhase
DBCOND0045917 (Malignant Neoplasm of Stomach)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03221426Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)Treatment
NCT03399110XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)Prevention
NCT03817268Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 ResectionTreatment
NCT03745170Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric CancerTreatment
NCT03006705Study of Adjuvant ONO-4538 With Resected Gastric CancerTreatment
NCT01917552Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05)Treatment
NCT03598348Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric CancerTreatment
NCT02555358Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical StudyTreatment
NCT01711242Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric CarcinomaTreatment
NCT02395640The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric CancerTreatment